Particle.news
Lupus Multiple Sclerosis Rheumatoid Arthritis Research Symptoms Sjögren's Syndrome Research Discoveries Treatment Options Psoriasis Mechanisms Myasthenia Gravis Stiff Person Syndrome Celiac Disease Graves' Disease Hashimoto's Disease Disease Mechanisms Spondyloarthritis Immune System Disorders Neurological Disorders Stiff-Person Syndrome Impact on Musicians Myositis Systemic Lupus Erythematosus Inflammation Sjögren’s Syndrome Lupus SLE Arthritis IgG4-Related Disease Gender Differences Rheumatism Research Developments Lyme Disease Guillain-Barre Syndrome Chronic Conditions Types of Autoimmune Diseases Diabetes Chronic Inflammation Vitiligo Type 1 Diabetes Therapeutic Approaches Espondiloartrite Axial Treatment Development Immune Regulation Treatment Methods Inflammatory Reactions Genetics B Cell Disorders Cancer Genetic Disorders Types of Autoimmune Disorders Sickle Cell Anemia Associated Conditions Health Awareness Types of Autoimmune Conditions Liver Transplant Fever Hashimoto's Thyroiditis Respiratory Autoimmune Diseases Sjogrens Syndrome Morbus Basedow Skin Disorders Ulcerative Colitis Sjogren's Syndrome Skin-Related Autoimmune Disorders Juvenile Myositis AnNa R. Addison's Disease Guillain-Barré Syndrome Nuclear Waste Exposure Infections Stiff Person Syndrome (SPS) Treatment Sex Bias Risk Factors Female Autoimmune Diseases Prevalence of Autoimmune Diseases Multifactorial Nature of Autoimmunity Specific Autoimmune Disorders Endometriosis Kidney Diseases Alopecia Neurological Health Conditions MS Symptoms Ankylosing Spondylitis Post-COVID Conditions Pregnancy Impact on Athletes Cancer Treatment Therapies Alopecia Areata Autoimmune Hepatitis Vascular Diseases Research Innovations
The program narrows to non‑relapsing secondary progressive MS, with the U.S. decision now expected by the end of the first quarter of 2026.
